文献速递免疫规划卫生政策与健康促进

新冠疫苗接种与非新冠死亡率风险:美国七家综合医疗组织研究

COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-10-29

经年龄性别标化及人口学特征和站点调整后,接种者非新冠死亡率低于未接种者,未发现死亡风险增加。

要点

  • 接种新冠疫苗后非新冠死亡率低于未接种者,未发现风险增加。
  • 辉瑞疫苗调整后相对风险第二剂为0.34,莫德纳为0.31。
  • 强生疫苗调整后相对风险为0.54,均提示无死亡风险增加。

核心结论

  • 接种新冠疫苗者非新冠死亡率低于未接种者,无死亡风险增加证据。

主要发现

  • 辉瑞疫苗非新冠死亡调整后相对风险第一剂0.41(95%CI 0.38-0.44),第二剂0.34(95%CI 0.33-0.36)。
  • 莫德纳疫苗调整后相对风险第一剂0.34(95%CI 0.32-0.37),第二剂0.31(95%CI 0.30-0.33)。
  • 强生疫苗调整后相对风险0.54(95%CI 0.49-0.59)。

临床怎么用

  • 可向公众说明接种新冠疫苗未增加非新冠死亡风险,以增强疫苗信心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

By September 21, 2021, an estimated 182 million persons in the United States were fully vaccinated against COVID-19.* Clinical trials indicate that Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Johnson & Johnson; Ad.26.COV2.S) vaccines are effective and generally well tolerated (1-3). However, daily vaccination rates have declined approximately 78% since April 13, 2021†; vaccine safety concerns have contributed to vaccine hesitancy (4). A cohort study of 19,625 nursing home residents found that those who received an mRNA vaccine (Pfizer-BioNTech or Moderna) had lower all-cause mortality than did unvaccinated residents (5), but no studies comparing mortality rates within the general population of vaccinated and unvaccinated persons have been conducted. To assess mortality not associated with COVID-19 (non-COVID-19 mortality) after COVID-19 vaccination in a general population setting, a cohort study was conducted during December 2020-July 2021 among approximately 11 million persons enrolled in seven Vaccine Safety Datalink (VSD) sites.§ After standardizing mortality rates by age and sex, this study found that COVID-19 vaccine recipients had lower non-COVID-19 mortality than did unvaccinated persons. After adjusting for demographic characteristics and VSD site, this study found that adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 (95% confidence interval [CI] = 0.38-0.44) after dose 1 and 0.34 (95% CI = 0.33-0.36) after dose 2. The aRRs of non-COVID-19 mortality for the Moderna vaccine were 0.34 (95% CI = 0.32-0.37) after dose 1 and 0.31 (95% CI = 0.30-0.33) after dose 2. The aRR after receipt of the Janssen vaccine was 0.54 (95% CI = 0.49-0.59). There is no increased risk for mortality among COVID-19 vaccine recipients. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Xu S, Huang R, Sy LS, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34710075. doi:10.15585/mmwr.mm7043e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。